Clinical Justification for iNO Therapy: Evidence, Patient Selection, and Reassessment

A defensible clinical justification for iNO therapy links an infant’s physiology, optimized ventilation and a measurable treatment goal. The Canadian Paediatric Society’s February 2023 guidance recommends considering iNO for late-preterm or term infants with hypoxemic respiratory failure despite optimized ventilation. Echocardiography can help assess for persistent pulmonary hypertension of the newborn and evaluate left ventricular function before treatment.

The rationale should reflect the individual patient and the limits of the evidence, especially when a proposed use falls outside established patient groups. A practical plan identifies the findings supporting consideration, the response measures and timing, and who will reassess the treatment. The Canadian Paediatric Society’s response guidance expects improved oxygenation within 30 minutes. If the expected response is not observed, decisions should follow the applicable protocol, including guidance on gradual weaning.

Clinical decisions and delivery planning are related but distinct. This article outlines how to document patient-specific findings, assess response and plan delivery workflow. It also explains where LungFit® PH may fit as an iNO delivery system within a clinician-led pathway.

What Clinical Question Can Justify Considering iNO Therapy?

A clinical justification for iNO therapy is a documented, patient-specific rationale connecting the patient’s physiology to a defined treatment goal. It should explain why a trial is being considered, not predict that treatment will produce a particular outcome. The proposed mechanism, evidence for the patient group, product labelling and local protocol all inform the decision. None should be treated as a substitute for the others, and meeting one criterion alone does not establish suitability.

iNO is considered in response to a clinical problem, not as routine therapy. The Canadian Paediatric Society’s February 2023 guidance recommends considering it for late-preterm or term infants with hypoxemic respiratory failure despite optimized ventilation. Echocardiography can help assess for persistent pulmonary hypertension of the newborn and left ventricular function. Foundational information on nitric oxide as a signalling molecule and vasodilator is available in Nitric Oxide: A Foundational Understanding; it does not replace clinical guidance or local protocols.

Which clinical problem is the team trying to address?

Begin by stating the problem iNO is intended to address and the change that would matter for this patient. If the record supports pulmonary hypertension and impaired oxygenation, explain how those findings relate to the treatment objective. For example, if the objective is improved oxygenation, identify the measures the team will use to assess it and ensure they are appropriate to the patient’s care context.

What makes a rationale patient-specific?

Connect the relevant findings to the proposed goal and name the team responsible for oversight. Consider the overall clinical picture, including diagnostic assessment and the response to optimized care, rather than treating a diagnosis as automatic eligibility. Before a trial, review the rationale against applicable evidence, current product labelling and institutional protocol. Recording these elements makes clear why iNO is being considered, how its response will be evaluated and who will reassess whether the plan remains appropriate.

How Does iNO’s Physiological Rationale Relate to Evidence and Limitations?

iNO has a plausible physiological rationale: it can relax pulmonary vascular smooth muscle, potentially lowering pulmonary vascular resistance and directing blood flow towards ventilated lung regions. This selective pulmonary vasodilation may improve ventilation-perfusion matching and oxygenation. A plausible mechanism or short-term change in oxygenation does not, by itself, establish patient-centred benefit for an individual infant.

What should clinicians understand about the proposed mechanism?

Pulmonary vascular resistance reflects the opposition to blood flow through the pulmonary vessels. In hypoxemic respiratory failure associated with pulmonary hypertension, iNO’s local vasodilatory action may improve perfusion of ventilated areas. The clinical response depends on the patient’s underlying physiology and care context. The mechanism alone cannot predict whether an individual patient will benefit.

How should evidence limitations shape the rationale?

Interpret evidence in the population and setting studied. The Canadian Paediatric Society’s February 2023 guidance addresses late-preterm and term infants with hypoxemic respiratory failure despite optimized ventilation. For this population, evidence supports a reduction in the combined outcome of death or need for extracorporeal membrane oxygenation. This finding is not a guaranteed survival benefit for an individual and should not be generalized to every neonatal group.

Keep immediate physiological measures, such as oxygenation, distinct from patient-centred outcomes, including survival or need for further support. The CPS guidance does not recommend routine iNO use in preterm infants. Consideration for a population or use outside established guidance requires careful review of current evidence, product labelling and institutional protocol. A sound clinical justification for iNO therapy states which evidence applies, what remains uncertain and how the team will assess the patient’s response.

When considering delivery workflow alongside clinical evidence, LungFit® PH iNO delivery information can inform equipment planning. It does not replace patient selection or protocol-based decisions.

How Should Clinicians Document an iNO Trial and Reassess Response?

A structured record connects the reason for a trial to its evaluation plan and the resulting decision. Document the baseline, goal, response measures, reassessment timing and responsible clinician. This makes the trial accountable to observed findings rather than assumption.

1. Document the baseline. Record the clinical findings and patient status before treatment, including the measures the team will use to evaluate the problem.
2. State the goal. Describe the intended clinical change for this patient, such as improved oxygenation when that is the treatment objective.
3. Define response measures and timing. Select institutionally approved measures suited to the patient and care setting. Record when reassessment will occur under the applicable protocol. For the population addressed by the CPS response guidance, note whether oxygenation improves within 30 minutes.
4. Reassess and record the decision. Compare the findings with baseline and the stated goal. Document the team’s decision to continue, adjust or discontinue treatment in keeping with protocol and product labelling.

What belongs in the clinical rationale?

Include the findings supporting consideration of iNO, the problem being addressed, the intended goal and the evidence relevant to this patient. Record applicable product labelling and institutional protocol, and identify the clinician responsible for oversight and reassessment. This gives the clinical justification for iNO therapy a clear link to the care plan and a record the team can follow.

How should response and non-response be handled?

At each planned review, compare the approved measures with the baseline and predefined goal. Record whether the findings support the intended objective, whether any changes require attention, and what the responsible team decides. If the goal is not met, document the reasoning for the next step under local criteria rather than assuming continued treatment is appropriate. Include relevant changes in care when interpreting the response.

Use the same protocol-led approach for delivery planning. Explore LungFit® PH for iNO delivery planning as your team considers equipment, staff readiness and established reassessment processes.

Where Does LungFit® PH Fit in a Clinically Justified iNO Pathway?

LungFit® PH is a delivery-system consideration, not a basis for deciding whether an infant is clinically eligible for iNO. The responsible care team establishes the patient-specific rationale, treatment goal and reassessment plan under applicable guidance and institutional protocols. Device selection follows those clinical decisions and should support the agreed care pathway, not be treated as evidence of a likely response.

What should a care team align before delivery?

Before therapy begins, align the treatment goal with the institutional protocol, monitoring plan and device workflow. Clarify team responsibilities, staff familiarity with the system and how delivery-related steps fit the unit’s established processes. The team should know how its approved monitoring and reassessment procedures will continue during treatment. Clinical eligibility and treatment decisions remain with the responsible clinicians.

How can Canadian-based support contribute to implementation?

Novus Medical distributes LungFit® PH, an iNO generator featuring patented Plasma Pulse Technology. Novus Medical provides Canadian-based technical support by phone, internet and remote connection to support healthcare facilities with device-related questions and workflow planning. Technical support complements, but does not replace, clinical training, local protocols or the care team’s responsibility for patient management.

For implementation planning, consider how staff readiness, equipment workflow and the protocol-governed treatment plan fit together before introducing the system into care. Keep the device evaluation focused on operational needs and the team’s ability to follow established delivery and monitoring procedures. Do not treat the choice of delivery system as a prediction of clinical outcome.

Explore LungFit® PH with Novus Medical as a delivery option for your facility’s clinician-led iNO pathway.

Turn the Rationale Into a Shared Care Plan

A clear clinical justification for iNO therapy gives the care team a disciplined starting point. Its value depends on carrying the plan through consistently. Align clinical oversight, documented goals, reassessment responsibilities and delivery workflow so decisions remain connected to the patient’s response and care is coordinated across the team.

For facilities evaluating delivery and implementation, LungFit® PH features patented Plasma Pulse Technology, with Canadian-based technical support available by phone, internet and remote connection. These operational considerations can inform planning. Patient selection and treatment decisions remain guided by clinicians, current product labelling and institutional protocols.

Discuss LungFit® PH and clinical implementation with Novus Medical to consider how the system fits your care team’s established pathway. Align roles and protocol requirements before implementation.

Frequently Asked Questions

What clinical conditions may support considering iNO therapy?

Selected cases of hypoxemic respiratory failure associated with pulmonary hypertension may prompt clinical review of iNO as an option. The assessment should also account for other factors that could explain the patient’s oxygenation pattern, such as changes in respiratory support or an evolving clinical condition. Recording these concurrent factors helps the team interpret later observations without attributing every change to iNO.

Does iNO therapy improve outcomes for every patient with hypoxaemia?

No. A response observed in one patient group or care setting should not be assumed in another. Interpretation also depends on the outcome being evaluated and whether other interventions changed during the same period. For example, a change in oxygenation alongside a change in ventilation does not, on its own, establish which intervention contributed. Keep these distinctions clear when discussing the clinical justification for iNO therapy.

How should clinicians assess whether an iNO trial is working?

Use consistent measurement conditions where clinically appropriate, and record when observations were made and whether care changed at the same time. This gives the team a clearer basis for interpreting trends than isolated values. If the patient’s condition or support changes during the trial, document that context alongside the findings so the review reflects the course of care, not just a single measurement.

Is iNO therapy appropriate for neonatal pulmonary hypertension?

It may be considered for some neonates, but the diagnosis alone does not establish whether it is appropriate for a particular infant. The neonatal team must interpret the clinical picture in light of the infant’s maturity, associated conditions and cardiac assessment, as well as current guidance and applicable labelling. The decision depends on whether the evidence and the infant’s circumstances support consideration in that specific case.

What should be documented before starting iNO therapy?

Make handover responsibilities clear alongside the clinical record: who will review the patient, how findings will be communicated and who can authorize a change under facility policy. Record any interruption or departure from the planned process and its clinical context. This supports continuity when care transfers between clinicians or teams and keeps decisions traceable.